Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

about

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

Item

http://www.wikidata.org/entity/Q43375008

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@en

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@nl

type

Item

label

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@en

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@nl

prefLabel

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@en

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@nl

P1476

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.

@en

P2093

Hazel B Nichols

http://www.w3.org/2001/XMLSchema#string

P2860

Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer: Data Points # 14

Epidemiology of ductal carcinoma in situ

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Adjuvant hormonal therapy use among women with ductal carcinoma in situ.

P304

6091709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/6091709

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Stacie B. Dusetzina

Aaron N Winn

Chelsea Anderson

P577

2017-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29056966

http://www.w3.org/2001/XMLSchema#string

P932

5615957

http://www.w3.org/2001/XMLSchema#string